JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY HYDERABAD Pharm. D V Year CLINICAL PHARMACOKINETICS AND PHARMACOTHERAPEUTIC DRUG MONITORING Previous Question Paper (October - 2020 - R08)

Pediatric dosing requires careful consideration due to physiological and developmental differences between infants, children, and adults. Because organ function, body composition, and metabolic pathways are immature or rapidly changing, standardized adult doses are inappropriate.

Key approaches to pediatric dosing include:

1. Age-based and Weight-based dosing: The most common method is calculating dose based on body weight (mg/kg). This is generally reliable for children older than one year.
2. Body Surface Area (BSA): BSA is often considered more accurate than weight alone for drugs with a narrow therapeutic index, as it correlates better with physiological functions like cardiac output and glomerular filtration rate.
3. Developmental Pharmacokinetics: Dosing must be adjusted for neonates and infants due to lower gastric acidity, higher total body water, lower plasma protein binding, and immature hepatic enzyme systems (e.g., glucuronidation) and renal clearance mechanisms.
4. Nomograms and Formulas: Traditional formulas like Young's or Clark's rule are largely historical and less accurate than modern weight-based protocols, which are now standard in clinical practice to minimize toxicity and ensure therapeutic efficacy.

Pharmacokinetic (PK) correlation in drug therapy refers to the relationship between the drug concentration in the body and the observed clinical response. This correlation is fundamental to Therapeutic Drug Monitoring (TDM) and the optimization of individualized dosage regimens.

Key aspects of PK correlation include:

1. Concentration-Effect Relationship: The intensity of a drug's effect is typically proportional to its concentration at the receptor site. Since plasma concentration is easier to measure, it serves as a surrogate marker for the concentration at the site of action.
2. Therapeutic Range: This is the range of plasma concentrations within which the drug is likely to be effective with minimal risk of toxicity. PK correlation allows clinicians to maintain patients within this window by adjusting doses based on clearance and volume of distribution.
3. Individualization: Factors such as age, renal impairment, hepatic disease, and drug-drug interactions alter PK parameters (e.g., half-life, clearance). PK correlation enables the prediction of how these changes will impact steady-state concentrations, allowing for preemptive dose adjustments.
4. Clinical Utility: By correlating PK data with clinical outcomes, practitioners can distinguish between therapeutic failure due to inadequate dosing (sub-therapeutic levels) versus failure due to disease resistance, thereby guiding rational pharmacotherapy.